Barclays Raises Hims & Hers Target After Novo Deal Clears
Barclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Discover the pros and cons of long term versus short term investing. Make informed decisions based on your financial goals.
28,015 articlesBarclays boosts its target on Hims & Hers Health as Novo Nordisk deal removes a key legal overhang, while Progyny see...
Sarepta Therapeutics surged about 20% after releasing early Phase 1/2 data for SRP-1001 and SRP-1003, signaling poten...
Shield AI just unveiled a landmark Series G round worth $1.5 billion, lifting its valuation to $12.7 billion and sett...
A growing number of newlyweds confront the mine-vs.-ours debt question as one partner considers wiping out the $28,00...
A lawyer-turned-DJ builds shipping-container sports clubs in refugee camps, blending grant funding with revenue from ...
Los Angeles County registered the largest population decline among U.S. counties last year, a trend shaping budgets a...
A CNBC analyst contends the FedEx selloff reflects misinterpretation of the income statement, not a collapse in deman...
Could the SanDisk brand—now part of Western Digital—spark a trillion-dollar valuation in five years? This article bre...
AGNT, Inc. has completed its corporate transformation, changing its name and moving its domicile to Texas. The move i...
AI-driven signals suggest XRP could break out to $1.40-$1.55 in the next 15 days, depending on clearing a key resista...
Is netflix stock cheap overvalued? This article dives into how to gauge Netflix's value using real-world metrics, sce...
July brought steadier ground for stocks as AI chip makers led a tech rally. This guide breaks down the drivers, what ...